case_images: PMC10611496_01
case_images: Timeline of patient treatment schema.
case_images: fimmu-14-1276295-g001.jpg
case_images: PMC10611496_01_fimmu-14-1276295-g001.jpg
case_images: f1
case_images: Treatment schema and response assessment of the patient are detailed in  Figure 1 .
case_images: (A) Flowcytometric analyses of CNS fluid at the time of diagnosis showing CD138 positive lambda clonal plasma cells and decreased CD38 positivity after Daratumumab therapy. (B) Flowcytometric analyses of CNS fluid after 2 cycles of Elranatamab showing decreased CD138 positive lambda clonal plasma cells.
case_images: fimmu-14-1276295-g002.jpg
case_images: PMC10611496_01_fimmu-14-1276295-g002.jpg
case_images: f2
case_images: Neurotoxicity), after two cycles of Elranatamab, CNS findings showed significantly increased clonal plasma cells ( Figure 2 ). Neurological symptoms regressed.
case_images: PET CT images are showing a complete remission before (on the top) and after (bottom) Elranatamab therapy.
case_images: fimmu-14-1276295-g003.jpg
case_images: PMC10611496_01_fimmu-14-1276295-g003.jpg
case_images: f3
case_images: PET CT scan showed complete remission after 4 cycles of therapy ( Figure 3 ).